ArticleBMC bioinformatics2023
MCL-DTI: using drug multimodal information and bi-directional cross-attention learning method for predicting drug-target interaction.
Article in BMC bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Computational approaches for drug-drug interaction prediction: a systematic review of data sources, modeling strategies, and evaluation frameworks.Frontiers in pharmacology · 2026Pooled it
- Multiscale cross modal fusion and cascaded signal propagation for drug target interaction prediction.iScience · 2026Article
- A Length-Adaptive LLM-Enhanced Method for Drug-Target Interaction Prediction.International journal of molecular sciences · 2026Article
- CME-KGDTI: integrating clustered mutations into knowledge graph embedding for drug-target interaction prediction.BioData mining · 2026Article
- MAGC-DTI: modality-shared space and adaptive gated interactive cross-attention for drug-target interaction prediction.Scientific reports · 2026Article
- A comprehensive review of neural network-based approaches for drug-target interaction prediction.Molecular diversity · 2026Review
- MFDR-DTI: Multisource Feature Decoupling and Dual-Level Reorganization Fusion for Accurate Drug-Target Interaction Prediction.ACS omega · 2026Article
- TriDTI: tri-modal representation learning with cross-modal alignment for drug-target interaction prediction.Briefings in bioinformatics · 2026Article
- Article
- A Systematic Review of Drug-Related InteractionsUtilizing Deep Learning and LLMs for Prediction and Mitigation.ACS omega · 2025Review
- Identifying novel therapeutic targets of natural compounds in traditional Chinese medicine herbs with hypergraph representation learning.Briefings in bioinformatics · 2025Article
- H2GnnDTI: hierarchical heterogeneous graph neural networks for drug-target interaction prediction.Bioinformatics (Oxford, England) · 2025Article
- Relational similarity-based graph contrastive learning for DTI prediction.Briefings in bioinformatics · 2025Article
- MFCADTI: improving drug-target interaction prediction by integrating multiple feature through cross attention mechanism.BMC bioinformatics · 2025Article
- The changing scenario of drug discovery using AI to deep learning: Recent advancement, success stories, collaborations, and challenges.Molecular therapy. Nucleic acids · 2024Review
- CCL-DTI: contributing the contrastive loss in drug-target interaction prediction.BMC bioinformatics · 2024Article
- GeNNius: an ultrafast drug-target interaction inference method based on graph neural networks.Bioinformatics (Oxford, England) · 2024Article
- Attention is all you need: utilizing attention in AI-enabled drug discovery.Briefings in bioinformatics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrediction of drug-target interaction (DTI) is an essential step for drug discovery and drug reposition. Traditional methods are mostly time-consuming and labor-intensive, and deep learning-based methods address these limitations and are applied to engineering. Most of the current deep learning methods employ representation learning of unimodal information such as SMILES sequences, molecular graphs, or molecular images of drugs. In addition, most methods focus on feature extraction from drug and target alone without fusion learning from drug-target interacting parties, which may lead to insufficient feature representation. MOTIVATION: In order to capture more comprehensive drug features, we utilize both molecular image and chemical features of drugs. The image of the drug mainly has the structural information and spatial features of the drug, while the chemical information includes its functions and properties, which can complement each other, making drug representation more effective and complete. Meanwhile, to enhance the interactive feature learning of drug and target, we introduce a bidirectional multi-head attention mechanism to improve the performance of DTI.
resultsTo enhance feature learning between drugs and targets, we propose a novel model based on deep learning for DTI task called MCL-DTI which uses multimodal information of drug and learn the representation of drug-target interaction for drug-target prediction. In order to further explore a more comprehensive representation of drug features, this paper first exploits two multimodal information of drugs, molecular image and chemical text, to represent the drug. We also introduce to use bi-rectional multi-head corss attention (MCA) method to learn the interrelationships between drugs and targets. Thus, we build two decoders, which include an multi-head self attention (MSA) block and an MCA block, for cross-information learning. We use a decoder for the drug and target separately to obtain the interaction feature maps. Finally, we feed these feature maps generated by decoders into a fusion block for feature extraction and output the prediction results.
conclusionsMCL-DTI achieves the best results in all the three datasets: Human, C. elegans and Davis, including the balanced datasets and an unbalanced dataset. The results on the drug-drug interaction (DDI) task show that MCL-DTI has a strong generalization capability and can be easily applied to other tasks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.